Passage Bio, Inc. Common Stock

PASGNASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
4.25 USD
↗ 0.24 (5.99%)AT CLOSE (03:59 PM EST)
4.16
↘ 0.09 (2.12%)
POST MARKET (AS OF 04:13 PM EST)
Post Market
AS OF 04:13 PM EST
4.16
↘ 0.09 (2.12%)
🔴Market: CLOSED

Shares of Passage Bio, Inc. Common Stock (PASG) are trading at $4.25. PASG shows a split signal: technical indicators suggest "Buy" while underlying fundamentals indicate "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On valuation, PASG trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Nov 13, 2026.

Open?$3.95
High?$4.25
Low?$3.95
Prev. Close?$4.01
Volume?11.9K
Avg. Volume?16.7K
VWAP?$3.98
Rel. Volume?0.71x
Bid / Ask
Bid?$3.40 × 200
Ask?$4.75 × 100
Spread?$1.35
Midpoint?$4.08
Valuation & Ratios
Market Cap?13.7M
Shares Out?3.2M
Float?2.9M
Float %?91.1%
P/E Ratio?N/A
P/B Ratio?273.51
EPS?-$10.28
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingBiotech - Drug Development›Neuroscience & CNS
Employees
24
Market Cap
12.9M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.passagebio.com
Listed
2020-02-28
Address
ONE COMMERCE SQUARE
PHILADELPHIA, PA 19103
Phone: (267) 866-0312
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
50
Short Sent.?
68
Piotroski F-Score?0/9Weak
Altman Z-Score?-54.11Distress
Confidence?48%Low
Full Fundamental Analysis →
Short InterestModerate
Short % of Float?1.69%Low
Short Interest?49.6K
Days to Cover?4.0
Free Float2.9M
Avg Daily Volume12.4K
Settlement Date2026-10-30
Financial Health
Current Ratio?1.00Adequate
Quick Ratio?1.00Adequate
Cash Ratio?0.97Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
3
273.51HIGH▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
Peers
100
S&P
97
0.2CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-66,164.0%WEAK▾
ROA?
S&P
3
-159.1%WEAK▾
Cash Flow & Enterprise
FCF?$-32645000
Enterprise Value?$-6484308
Fundamentals ratios updated end of day
MarketsMoversWatchlist